Biogen Publishes EMPAVELI Data Showing Reduced Proteinuria In Adolescents With Kidney Diseases

Biogen announced publication of adolescent subgroup data from Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases. The drug achieved a 71% response rate for 50% proteinuria reduction, with safety consistent across trial populations.